Spine News and Research

RSS

KYPHON ActivOs 10 Bone Cement with HA launched to treat patients with VCFs

Medtronic, Inc. today announced the launch of KYPHON ActivOs 10 Bone Cement with Hydroxyapatite, a polymethylmethacrylate bone cement containing hydroxyapatite for use in the treatment of patients with vertebral compression fractures who are undergoing minimally invasive surgery with KYPHON Balloon Kyphoplasty.

22 Jun 2010

Richmond Bone & Joint Clinic deploys NCR MediKiosk patient self-service solution

Richmond Bone & Joint Clinic (RBJC), an orthopedic specialty practice, has deployed the leading patient self-service solution from NCR Corporation in three of its four Houston-area locations. The NCR MediKiosk solution automates and speeds routine processes by allowing RBJC patients to check-in for scheduled appointments and remit co-pays and outstanding balances via self-service kiosks.

18 Jun 2010

Bacterin International to distribute biologic products to Broadlane network of medical institutions

Bacterin International, Inc., a developer of revolutionary bone graft material, today announced a three-year agreement to provide its biologic line of products, OsteoSponge®, OsteoSelect®, OsteoSponge SC®, OsteoWrap®, BacFast®, and OsteoLock®, to the vast Broadlane® nationwide network of hospitals and medical practices.

17 Jun 2010

Scientists receive over $3M to launch training and mentorship programs for promising young researchers

Scientists from the Universit- de Montr-al and its affiliated engineering school, -cole Polytechnique, have received major funding from the National Sciences and Engineering Research Council of Canada. Over $3 million was awarded to enable both institutions to launch training and mentorship programs for promising young researchers.

17 Jun 2010

Study examines survival rates of CF patients with MRSA

A team of researchers led by Elliott Dasenbrook, MD, MHS, Assistant Professor of Medicine and Pediatrics at Case Western Reserve University School of Medicine and Associate Director of the Adult Cystic Fibrosis Program at University Hospitals Case Medical Center's Rainbow Babies & Children's Hospital today published the findings from a major study about cystic fibrosis survival rates in the June 16 issue of JAMA.

16 Jun 2010

joimax moves into larger premises in Germany, US

The medical devices company joimax(R) GmbH is moving into new premises both in Germany and the US. "Growth requires space" had already been the motto of the last company move back in 2005.

16 Jun 2010

Diversity publication recognizes UH as a leader among health care institutions

DiversityInc, a leading publication on diversity and business, has recognized University Hospitals as a leader among health care institutions in its first ever Top Hospital Systems listing.

15 Jun 2010

ARBs increase risk of cancer: Study

University Hospitals Case Medical Center cardiologists have uncovered new research showing an increased risk of cancer with a group of blood pressure medications known as angiotensin-receptor blockers (ARBs).

14 Jun 2010

Accuray forms strategic alliance with Siemens

Accuray, a global leader in the field of radiosurgery, today announced that it has formed a strategic alliance with Siemens. The strategic alliance is expected to extend the global sales reach for Accuray's CyberKnife Robotic Radiosurgery System while creating a research-and-development alliance aimed at developing and commercializing innovative new technologies and products.

9 Jun 2010

Integra LifeSciences announces over 800 implantations of Vu a-POD fusion device

Integra LifeSciences announced today a major milestone in the commercialization of the Vu a-POD™ anterior lumbar intervertebral body fusion (ALIF) device. Launched in the U.S. in early 2009, the Vu a-Pod™ fusion device has now been implanted in over 800 patients in the U.S.

8 Jun 2010

MiMedx' HydroFix Vaso Shield receives FDA clearance for additional thicknesses and sizes

MiMedx Group, Inc., an integrated developer, manufacturer and marketer of patent protected biomaterial-based products, announced today that it has received notification by the FDA that the Company's proprietary device, HydroFix™ Vaso Shield, has received 510(k) clearance for additional thicknesses and sizes.

7 Jun 2010

Array BioPharma presents positive Phase 1 clinical data of ARRY-520 KSP inhibitor for multiple myeloma

Array BioPharma Inc. today announced the presentation of positive Phase 1 clinical data for its novel kinesin spindle protein (KSP) inhibitor, ARRY-520. The data, which were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, indicate that ARRY-520 was well tolerated and has shown encouraging preliminary results in the treatment of multiple myeloma.

7 Jun 2010

Novel brain mechanism promises new and effective anesthetics

A brain mechanism involved in both dreaming and waking from sleep may hold the key to new, more effective anesthetics and stimulants, reported neuroscientists at the University of Arkansas for Medical Sciences (UAMS).

4 Jun 2010

Anulex Technologies completes $20M Series E financing round

Anulex Technologies, Inc., a privately held medical device manufacturer focusing on soft tissue Preservation & Anular Repair products, announced the first closing of its fifth round of private equity financing which will total a minimum of $20 million. The Series E round was led by a new unnamed strategic investor with participation from existing investors Affinity Capital, Delphi Ventures, MB Venture Partners, New Enterprise Associates, SightLine Partners and Split Rock Partners.

4 Jun 2010

Tips to prevent back injuries

Whether moving to a new home or packing up for the semester, the physical intensity of moving can be extreme. Packing boxes, moving heavy furniture, emptying overhead cabinets -- all come with some risk for injury, especially to your back. Back pain is one of the most common reasons for Americans visit their doctors.

3 Jun 2010

Amedica secures US patent for novel hip implant

Amedica Corporation, a spinal and orthopaedic implant and instrument manufacturer focused on unique silicon nitride (SiN) ceramic technologies, announced today that it has been granted United States Patent No. 7,695,521 covering its novel hip implant featuring a monoblock ceramic acetabular cup for use in articulating joints for total joint replacement.

3 Jun 2010

Excess levels of a protein associated with TNF may produce cognitive decline: Studies

Two new studies suggest that excess levels of a protein associated with inflammation, TNF, may produce cognitive decline. TNF regulates both inflammation and brain function. TNF is elevated in the blood in many autoimmune diseases, and in the fluid surrounding the brain in Alzheimer's disease.

2 Jun 2010

RepRegen reports 3-month data from study of StronBone bioactive glass with Strontium

RepRegen™, the 'smart biomaterials' company previously known as BioCeramic Therapeutics, announced today that three-month data from an in vivo study of its StronBone™ bioactive glass with Strontium demonstrated that it can generate bone quality in and around defects that appears by analytical tests to be significantly superior to a standard bone void filler in the control defect.

2 Jun 2010

Pioneer announces presentation of NuBac IDE feasibility study 2-year follow up results at 10th SAS meeting

Pioneer Surgical Technology, Inc. is pleased to announce that the clinical results of the two-year follow up on the NuBac IDE feasibility study patients was presented at the recent 10th annual meeting of The International Society for the Advancement of Spine Surgery (SAS) in New Orleans by Domagoj Coric, M.D., Chief, Department of Neurosurgery, Carolina's Medical Center.

2 Jun 2010

Amgen's Prolia receives FDA approval for treatment of postmenopausal women with osteoporosis

Amgen Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Prolia™ (denosumab) for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. Prolia, the first and only FDA-approved RANK Ligand inhibitor, is an every six month 60 mg subcutaneous injection administered by a health care professional.

2 Jun 2010

Spine News and Research

KYPHON ActivOs 10 Bone Cement with HA launched to treat patients with VCFs

Richmond Bone & Joint Clinic deploys NCR MediKiosk patient self-service solution

Bacterin International to distribute biologic products to Broadlane network of medical institutions

Scientists receive over $3M to launch training and mentorship programs for promising young researchers

Study examines survival rates of CF patients with MRSA

joimax moves into larger premises in Germany, US

Diversity publication recognizes UH as a leader among health care institutions

ARBs increase risk of cancer: Study

Accuray forms strategic alliance with Siemens

Integra LifeSciences announces over 800 implantations of Vu a-POD fusion device

MiMedx' HydroFix Vaso Shield receives FDA clearance for additional thicknesses and sizes

Array BioPharma presents positive Phase 1 clinical data of ARRY-520 KSP inhibitor for multiple myeloma

Novel brain mechanism promises new and effective anesthetics

Anulex Technologies completes $20M Series E financing round

Tips to prevent back injuries

Amedica secures US patent for novel hip implant

Excess levels of a protein associated with TNF may produce cognitive decline: Studies

RepRegen reports 3-month data from study of StronBone bioactive glass with Strontium

Pioneer announces presentation of NuBac IDE feasibility study 2-year follow up results at 10th SAS meeting

Amgen's Prolia receives FDA approval for treatment of postmenopausal women with osteoporosis

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News